Mitsubishi Tanabe Pharma Corporation
http://www.mt-pharma.co.jp/e/index.php
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Mitsubishi Tanabe Pharma Corporation
Medtechs Are Fully Engaged In Climate Change: ‘They Have No Choice’
The E in ESG: SUDs, reuse, disposables, refurbishing, reprocessed devices? Multiple panelists at the 2024 MedTech Forum addressed the role medtech manufacturers should have in the climate change challenge.
Decoding Regulatory Agency Decisions: The Case of Amylyx’s Relyvrio/Albrioza in the US and EU
Relyvrio/Albrioza, Amylyx’s ill-fated treatment for amyotrophic lateral sclerosis, was approved for marketing by the US Food and Drug Administration but rejected by the European Medicines Agency. The Pink Sheet explores how the two agencies applied the available regulatory flexibilities and the impact of other factors, such as regulatory precedence and patient influence, on decision-making.
Scorpion Sinks Pincers Into Funding Round For PI3K Inhibitor
The oncology-focused start-up announced it closed a $150m series C financing that it plans to use to advance STX-478.
Cautious Optimism Greets Lexeo’s LX2006 For Friedreich’s Ataxia
The company’s shares fell amid debate over improvements in LVMI, but an analyst pointed out that they indicated the gene therapy has efficacy in Friedreich ataxia cardiomyopathy.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Nutraceuticals
- OTC, Consumer
- Vaccines
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- BIXEN Corporation
- Medicago Inc.
- Mitsubishi Tanabe Pharma America, Inc. (MTPA)
- Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA)
- Mitsubishi Tanabe Pharma Singapore Pte. Ltd.
- NeuroDerm, Ltd. (NDRM)
- PT Mitsubishi Tanabe Pharma Indonesia
- Mitsubishi Tanabe Pharma (Thailand)
- MT Pharma Singapore PTE. Ltd.
- Tai Tien Pharmaceuticals Co., Ltd.
- Tanabe Research Laboratories U.S.A.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice